Skip to main content

GENERAL COMMENTARY article

Front. Endocrinol., 09 June 2015
Sec. Cancer Endocrinology
Volume 6 - 2015 | https://doi.org/10.3389/fendo.2015.00098
This article is part of the Research Topic Transcriptional Regulation in Cancers and Metabolic Diseases View all 13 articles

Corrigendum: “Cancer cell gene expression modulated from plasma membrane integrin αvβ3 by thyroid hormone and nanoparticulate tetrac”

This article is a commentary on:

  1. Cancer Cell Gene Expression Modulated from Plasma Membrane Integrin αvβ3 by Thyroid Hormone and Nanoparticulate Tetrac

    1. Read original article
\r\n Paul J. Davis,*Paul J. Davis1,2*Gennadi V. GlinskyGennadi V. Glinsky3Hung-Yun LinHung-Yun Lin4John T. LeithJohn T. Leith5Aleck HercbergsAleck Hercbergs6Heng-Yuan TangHeng-Yuan Tang2Osnat Ashur-Fabian,Osnat Ashur-Fabian7,8Sandra IncerpiSandra Incerpi9Shaker A. Mousa\r\n Shaker A. Mousa2
  • 1Department of Medicine, Albany Medical College, Albany, NY, USA
  • 2Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA
  • 3Stanford University, Palo Alto, CA, USA
  • 4Taipei Medical University, Taipei, Taiwan
  • 5Rhode Island Nuclear Science Center, Narragansett, RI, USA
  • 6Cleveland Clinic, Cleveland, OH, USA
  • 7Hematology Institute and Blood Bank, Meir Medical Center, Kfar-Saba, Israel
  • 8Department of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  • 9Department of Sciences, University Roma Tre, Rome, Italy

A corrigendum on

Cancer cell gene expression modulated from plasma membrane integrin αvβ3 by thyroid hormone and nanoparticulate tetrac
by Davis PJ, Glinsky GV, Lin H-Y, Leith JT, Hercbergs A, Tang H-Y, et al. Front Endocrinol (2015) 5:240. doi: 10.3389/fendo.2014.00240

In Table 2, the section designated “Disabling of cell survival pathway gene expression,” line 5 incorrectly states “…pro-apoptotic miR-21”; the correct statement is “…pro-apoptotic miR-15A.” The issue is correctly discussed in the body of the published text, p. 2, right column, paragraph 4.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: integrin, thyroid hormone, tetraiodothyroacetic acid (tetrac), nano particle, gene expression, corrigendum

Citation: Davis PJ, Glinsky GV, Lin H-Y, Leith JT, Hercbergs A, Tang H-Y, Ashur-Fabian O, Incerpi S and Mousa SA (2015) Corrigendum: “Cancer cell gene expression modulated from plasma membrane integrin αvβ3 by thyroid hormone and nanoparticulate tetrac”. Front. Endocrinol. 6:98. doi: 10.3389/fendo.2015.00098

Received: 27 May 2015; Accepted: 27 May 2015;
Published: 09 June 2015

Edited by:

Wen Zhou, Columbia University, USA

Reviewed by:

Jean-Yves Scoazec, Université Lyon 1, France

Copyright: © 2015 Davis, Glinsky, Lin, Leith, Hercbergs, Tang, Ashur-Fabian, Incerpi and Mousa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Paul J. Davis, pdavis.ordwayst@gmail.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.